



# 1 Prevalence of Chikungunya, Dengue, and West Nile arboviruses in Iran based on enzyme-linked 2 immunosorbent assay (ELISA): A systematic review and meta-analysis

3 Ebrahim Abbasi<sup>1,2\*</sup> , Mohammad Djaefar Moemenbellah-Fard<sup>1,2</sup> 

4 <sup>1</sup>*Research Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences,*  
5 *Shiraz, Iran*

6 <sup>2</sup>*Department of Biology and Control of Disease Vectors, School of Health, Shiraz University of*  
7 *Medical Sciences, Shiraz, Iran*

8 \* [abbasie.ebrahim@gmail.com](mailto:abbasie.ebrahim@gmail.com), [e\\_abbasie@sums.ac.ir](mailto:e_abbasie@sums.ac.ir)

9

## 10 Author Summary

11 Arboviruses, including Chikungunya (CHIKV), Dengue (DENV), and West Nile (WNV), pose significant  
12 health threats globally, with increasing infections reported, including in Iran. This report conducts a  
13 systematic review and meta-analysis of the seroprevalence of these viruses in Iran through ELISA testing.  
14 A total of twelve studies published from 2000 to 2024 were analyzed, revealing a seroprevalence of  
15 12.9% for WNV and 6.2% for CHIKV, while DENV showed a mixed prevalence of 0% in one study and  
16 5.6% in another. The results suggest that WNV and CHIKV are widespread in Iran, whereas DENV  
17 appears to be sporadic.

18

## 19 ABSTRACT

20 **Introduction:** Arboviruses, including Chikungunya (CHIKV), Dengue (DENV), and West Nile (WNV)  
21 viruses, are significant viral threats that affect numerous people globally each year. This report explores  
22 the prevalence of these viruses in Iran through a systematic review and meta-analysis.

23 **Methods:** The present survey was performed with a systematic review and meta-analysis method on the  
24 seroprevalence of WNV, CHIKV, and DENV using the ELISA test. Based on this, by search in Web of  
25 Science, PubMed, Scopus, Cochrane Library, Science Direct, and Google Scholar scientific databases, all  
26 relevant published papers were sorted out and reviewed. Power ratification of data was carried out with a  
27 random effects model in meta-analysis, meta-regression,  $I^2$  index, and Egger test.

28 **Results:** Twelve published papers between 2000 and 2024 were embodied in this meta-analysis report.  
29 The seroprevalence of positive ELISA test for WNV in Iran was estimated at 12.9% (CI=95%: 7.4-18.4),  
30 and for CHIKV at 6.2% (CI=95%: 0.6-11.8). Regarding DENV, only two studies were conducted with a  
31 zero prevalence in one study, and a seroprevalence of 5.6% in another study.

32 **Conclusion:** According to these data, WNV, CHIKV, and DENV fevers have been detected in Iran using  
33 ELISA test. Considering the seropositivity of WNV and CHIKV, and the finding of these viruses from  
34 several provinces, it could be for granted that these two viruses are ubiquitous and DENV fever is  
35 sporadic in Iran.

36 **Keywords:** Arbovirus, Chikungunya, Dengue, ELISA, Meta-analysis, Virus, WNV.

37

## 38 Introduction

39 West Nile virus (WNV) is a single strand positive sense RNA virus in the Flaviviridae family, which is  
40 mainly transmitted by *Culex* and *Aedes* mosquitoes. *Culex pipiens*, *Culex tarsalis*, and *Aedes vexans* are  
41 the main vectors of WNV<sup>1 2</sup>. In Iran, *Cx. pipiens* and *Ae. caspius* are vectors of WNV. Trans-ovarian  
42 transmission of WNV among mosquito vectors is also possible, which renders them reservoirs of this  
43 pathogen. WNV circulates between insects, birds, and mammals (as the dead-end host), and their life is  
44 maintained in a cycle of "amplification"<sup>2</sup>. The virus cannot transfer between mammals, especially  
45 humans to humans, and can only be transmitted to another person through organ transplants or blood  
46 transfusions, and placental/ milk transmission. Accidental human infection is often (~80%) asymptomatic,  
47 in 20% of cases with mild flu-like symptoms, and <1% can cause WNV neurotropic disease (WNND,  
48 West Nile Neuro-invasive Disease), which usually occurs in elderly and immunocompromised  
49 individuals, that can lead to death<sup>3-6</sup>.

50 Migratory birds play important roles in the transmission and spread of WNV in the world, so today, this  
51 virus is prevalent in most parts of the world, including Europe and Asia. Since no effective and safe  
52 vaccine is available to deal with this virus<sup>7</sup>, organizations and departments related to health have  
53 suggested that WNV monitoring plans be implemented in the form of collecting virologic, entomologic,  
54 veterinary, and epidemiologic data to monitor the spread of WNV, and identify cases of human infection  
55 so that prevention, control, and adoption of appropriate treatment protocols to deal with this virus could  
56 be undertaken<sup>8-10</sup>.

57 Dengue virus (DENV) is also a single strand positive sense RNA virus in the Flaviviridae family, and the  
58 causative agent of the newly-emergent dengue fever which has four serotypes 1, 2, 3, and 4<sup>11</sup>. The  
59 primary and secondary vectors of DENV are *Aedes aegypti* and *Aedes albopictus* mosquitoes<sup>12</sup>. Trans-  
60 ovarian transmission of DENV among vectors is possible. The life of all four DENV serotypes is  
61 maintained in two sylvatic and urban cycles. The Asian tiger mosquito, *Ae. albopictus*, serves as a  
62 "bridge" vector between these two cycles. Both these diurnally-active anthropophilic *Aedes* vectors are  
63 increasingly reported from SE Iran. In the sylvatic cycle, the virus is transmitted from non-human  
64 mammals to mosquitoes, and then to mammals, such as the monkey-*Aedes*-monkey cycle, which is  
65 ecologically and evolutionarily distinct from the human transmission cycle<sup>13</sup>.

66 More than 400 million infections, and >20,000 deaths occur annually due to DENV worldwide<sup>11 14</sup>. This  
67 disease often exists as a latent or asymptomatic infection, and in endemic/ epidemic forms in different  
68 regions of the world<sup>11</sup>. Low-to-medium viremia in these persons could be infectious to mosquitoes. The  
69 continents of Asia, America, Africa, and Australia witness DENV epidemics every year<sup>15</sup>. Clinical  
70 manifestations of dengue infection range from mild fever to severe dengue hemorrhagic fever (DHF).  
71 Infection with one serotype of DENV can provide lifelong immunity to the same serotype, while  
72 secondary infection with other serotypes levitates the risk of infection to severe DENV. No effective  
73 vaccine is available for this virus<sup>16</sup>.

74 Chikungunya virus (CHIKV) is a single strand positive sense RNA virus of the alphavirus genus in  
75 Togaviridae family. Alphaviruses can cause inflammatory musculoskeletal diseases with debilitating  
76 symptoms such as arthritis, arthralgia, and myalgia in humans<sup>17</sup>. CHIKV is transmitted by *Aedes*  
77 mosquitoes, especially *furcifer*, *africanus*, *aegypti*, *albopictus*, and *Stegomyia* species<sup>18 19</sup>. This virus has  
78 three genotypes, namely West Africa (WA), East/Central/Southern Africa (ECSA), and Asian. All three

79 genotypes are distributed worldwide, but ECSA and Asian genotypes are more common<sup>19-21</sup>. The virus is  
80 maintained in a rural enzootic transmission cycle or the sylvatic cycle between *Aedes* mosquitoes and  
81 animal reservoirs. However, today the virus has adapted to urban cycles, and no longer requires the  
82 presence of non-human primates or the sylvatic cycle for their maintenance<sup>22</sup>.

83 Unlike DENV, CHIKV is not life threatening. Mortality caused by this virus is low, but it can cause  
84 severe complications, and affect people's quality of life. In most cases, CHIKV infection presents with a  
85 sudden onset of fever accompanied by joint pain. In minor cases, it leads to polyarthralgia and debilitating  
86 arthritis, rashes, myalgia, and headache<sup>23</sup>. Asymptomatic infection is rare and occurs in 3-28% of cases in  
87 epidemics<sup>24 25</sup>. The infection is often self-limiting, and the patient eventually recovers, but some patients  
88 develop persistent joint pain that may persist for months or years after the acute stage of the disease<sup>26 27</sup>.  
89 Approximately 30–40% of infected individuals experience some long-term complications<sup>28</sup>. So far, no  
90 vaccine is available to prevent this virus<sup>18</sup>.

91 ELISA (Enzyme-linked immunosorbent assay) test is a method of serological examination of viruses in  
92 the world. Due to its high sensitivity, and low false positive rate of about 20%, this test is recommended  
93 as a serological test for the initial screening of viral diseases. The presence of DENV IgG antibodies in  
94 people indicates that they have been infected with the virus in the past or present, which is usually  
95 investigated in the ELISA test<sup>29</sup>.

96 Due to the lack of an effective vaccine to prevent viral infections of arboviruses and the existence of  
97 complications and death caused by these viruses, awareness of the prevalence, distribution, and detection  
98 methods of these viruses to adopt control and prevention programs is essential. The named viral diseases  
99 have been known in Iran in the past years. However, their prevalence is different in different regions of  
100 Iran. Accordingly, this study was conducted to determine the positive rate of ELISA test for WNV,  
101 DENV, and CHIKV by a systematic review and meta-analysis method in Iran, to achieve comprehensive  
102 results regarding the spread of these viruses.

## 103 **Materials and Methods**

### 104 ***Study Protocol***

105 This study was conducted by the method of systematic review and meta-analysis in the field of ELISA  
106 tests for the three arboviruses of WNV, CHIKV, and DENV based on the guidelines of PRISMA  
107 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)<sup>30</sup>.

### 108 ***Search Strategy***

109 In the initial search, all English-language articles published from the beginning of 2000 to the end of May  
110 2024 were extracted by searching the Web of Science, PubMed, Scopus, Cochrane Library, Science  
111 Direct, and Google Scholar databases. Search for articles using the keywords Arbovirus, West Nile Virus,  
112 West Nile Virus Infection, WNV, West Nile Virus IgG, IgG anti-WNV, Dengue Fever, Dengue virus,  
113 Dengue virus infection, Chikungunya virus, Enzyme-linked immunosorbent assay, ELISA, Serology,  
114 Seroprevalence, Seropositivity, Iran, Iranian in the title, abstract and keywords were done in singular and  
115 compound form using “AND” and “OR” operators.

### 116 ***Inclusion and Exclusion Criteria***

117 All the English-language articles published in Iran were in the field of arboviruses: WNV, CHIKV, and  
118 DENV. The serological examination of the virus was done using the ELISA test, the positive rate of  
119 ELISA test was reported with good quality. These were entered into the study. Articles that did not meet  
120 the inclusion criteria or were conducted using meta-analysis, review, case report, or case series methods  
121 were excluded from the study.

### 122 ***Quality Assessment***

123 The quality assessment of the articles was done based on 22 parts of the STROBE (Strengthening the  
124 Reporting of Observational Studies in Epidemiology) checklist, which examined compliance with the  
125 principles of writing and implementation in the title, the method of reporting findings, limitations, and  
126 conclusions. Each part of this checklist is given a score based on its importance, and the maximum  
127 possible score is 33<sup>31</sup>.

### 128 ***Screening and Data Extraction***

129 The articles were screened by two researchers independently by examining the title and abstract of the  
130 articles and considering the inclusion and exclusion criteria. Finally, the full text of the articles was  
131 investigated by two researchers independently, and if the articles were rejected by two people, the reason  
132 was mentioned, and in case of disagreement between them, the article was refereed by a third person.  
133 Data extraction was done using a pre-prepared checklist that included study location, study time, sample  
134 size, type of serological test, number of positive ELISA tests, and type of virus under investigation.

### 135 ***Study Selection***

136 In the initial search and considering the inclusion criteria, 794 articles were extracted. Then, using the  
137 Endnote software, the duplication of sources was investigated, and 259 articles were excluded from the  
138 study due to duplication. Then, by investigating the titles and summaries of the articles, 486 articles were  
139 excluded from the study due to their irrelevance. After reviewing the full text of the articles, 37 articles  
140 were excluded due to the lack of investigation on the prevalence of the ELISA test and the unknown  
141 population. Finally, 12 articles entered the meta-analysis process (Figure 1).

### 142 ***Statistical Analysis***

143 In order to combine the results in heterogeneous studies, random-effects model was used, and in the  
144 homogeneous studies, the fixed-effects model in meta-analysis was deployed. To investigate the  
145 heterogeneity of the data,  $I^2$  and Cochrane Q tests were used. Publication bias was controlled by Egger  
146 test, and funnel plot and data analysis were performed using STATA ver. 17.0 software.

### 147 **Results**

148 Overall, 12 articles that were conducted in Iran between 2010 and 2023 were included in this meta-  
149 analysis process. Nine articles on WNV<sup>29 32-39</sup>, three articles on CHIKV<sup>38 40 41</sup>, and two articles on DENV  
150<sup>29 42</sup> were scrutinized. The characteristics of the articles included in the meta-analysis are presented in  
151 Table 1.

152 Nine articles with a sample size of 3013 people in the field of WNV serology in Iran were included in the  
153 meta-analysis process. Based on these findings, the prevalence of WNV was estimated to be 12.9% using  
154 the ELISA serology test in Iran. Among the surveyed studies, the highest prevalence of WNV positive  
155 tests was related to that conducted in Fars province with a prevalence of 27.3%, and the lowest prevalence  
156 of the test related to the studies carried out in Golestan, Gilan, and Qom provinces with a prevalence of  
157 1.3% (Figure 2).

158 The meta-analysis of three studies performed on the prevalence of positive CHIKV assay in Iran showed  
159 that 6.2% of the studied population had a positive ELISA test in this regard (Figure 3). The prevalence of  
160 positive Dengue fever virus ELISA test in Iran was also investigated in two studies. In one survey <sup>42</sup>,  
161 there was no case of positive ELISA test in the field of DENV, while the prevalence of this virus was  
162 reported at 5.6% in the other study <sup>43</sup> conducted in Sistan-Baluchistan province <sup>29 43</sup>.

163 The publication bias was evaluated using a funnel plot and Egger test. Considering the symmetry of the  
164 funnel plot and the fact that the studies with a high sample size are placed under the plot, it can be  
165 mentioned that the publication bias did not occur ( $P = 0.12$ ) (Figure 4). Although several studies with a  
166 smaller sample size are outside the graph, it shows that to make a general consensus, it is necessary to  
167 conduct another series of studies in this field. Investigating the prevalence of positive ELISA tests based  
168 on the current sample volumes showed that with the increase in sample size, the prevalence of positive  
169 ELISA tests has also increased (Figure 5).

## 170 Discussion

171 Based on the findings of this meta-analysis using the ELISA serology test in Iran, the WNV prevalence  
172 was estimated to be 12.9% (95%, CI: 18.4-7.4). In the past decades, WNV has spread in most regions of  
173 the world, which has affected its virulence, pathogenicity, epidemiology, and hosts. WNV has caused  
174 major epidemics with thousands of human morbidity cases and mortality in the world <sup>44</sup>. This virus is  
175 endemic in the Middle East, in the countries of Pakistan, Jordan, Turkey, Iraq, Oman, Saudi Arabia,  
176 Sudan, Yemen, Egypt and Afghanistan <sup>45-47</sup>. The prevalence of WNV was 26.6% in Pakistan, 30.4% in  
177 Afghanistan, and 10.4% in Qatar <sup>48 49</sup>. In Iraq (11.6-15.1%), Egypt (1-61%), Jordan (8%), Iran (0-30%),  
178 Libya (2.3%), Lebanon (0.5-1%), Pakistan (0.6-65.0%), Morocco (0-18.8%), Tunisia (4.3-31.1%), and  
179 Sudan (2.2-47%) have been reported <sup>50</sup>.

180 The WNV virus is ubiquitously endemic in Iran. Various factors, including weather conditions such as  
181 temperature and relative humidity fluctuations, can affect the activity of this virus vector, as a result, its  
182 prevalence varies in different regions of the country <sup>51</sup>. In general, the prevalence of WNV in Iran is close  
183 to the endemic areas and neighboring countries of Iran. According to the results of surveys included in  
184 this meta-analysis process, the prevalence of this virus in the southern provinces was higher than in the  
185 northern and western provinces of Iran, which can be related to the increased amplification of its virus  
186 vectors in the south, and neighboring countries of Iran, which have a higher prevalence of this virus. In  
187 general, the prevalence of WNV in Iran is relatively high, and it is necessary to evaluate the circulation of  
188 this virus in Iran every year, and implement preventive measures to mitigate the spread of this virus in the  
189 country.

190 The results of meta-analysis on the prevalence of positive ELISA test for CHIKV showed that this virus  
191 prevalence was 6.2% (95%, CI: 0.6-11.8) in Iran. Studies have shown that the prevalence of CHIKV  
192 varies in different regions of the world. Its epidemics occur every 7-8-year period. The CHIKV is not life-  
193 threatening in contrast to DENV. The prevalence of CHIKV has been reported in Italy as 10.2% <sup>52</sup>, in  
194 India as 22.3% <sup>53</sup>, in Tanzania as 3.7% <sup>54</sup> and in Turkey as 0.4% <sup>55</sup>. Also, the presence of CHIKV has  
195 been reported only in Saudi Arabia, Pakistan, Sudan, Yemen, Somalia, Egypt, Oman, Iraq, and Kuwait,  
196 and is known to be endemic in many parts of these regions <sup>8 56</sup>. In general, it can be mentioned that this  
197 disease has a relatively high prevalence in Iran, and Iran can be considered as an endemic region for  
198 CHIKV. Although this disease causes more complications to people, and its attenuation is relatively low,

199 knowing its prevalence is essential for control programs. Based on this, it is necessary to assess and  
200 monitor the serological prevalence of this virus annually.

201 With regard to Dengue fever virus (DFV), only one study which was conducted in Sistan-Baluchistan, the  
202 prevalence of this virus was 5.6%<sup>43</sup>. Other studies were conducted in the form of reports of Dengue fever  
203 in Tehran (2012 and 2009)<sup>57,58</sup>, and it showed that this virus was detected in different years in Iran. But  
204 apart from the SE regions of Iran, it has occurred sporadically in other regions. It should be noted that  
205 most of these cases were often reported as imported cases.

206 Dengue fever is recognized as a disease in developing countries of SE Asia, and most cases occur in these  
207 countries<sup>59</sup>. Pakistan, Yemen, Saudi Arabia, Madagascar, and Sudan are among the countries where  
208 dengue fever is reported as endemic<sup>60</sup>. In India, the prevalence of dengue fever is 23%, and in Sudan, it is  
209 47.6%<sup>61,62</sup>. These countries and SE Asian countries are often considered tourist destinations for Iranians,  
210 and many people from Iran travel to these countries every year. As a result, the possibility of contracting  
211 DFV, and transferring it inside the country increases, especially among travelers returning from Saudi  
212 Arabia following pilgrimage<sup>57,63</sup>. In general, it can be mentioned that cases identified in other provinces  
213 of Iran, except Sistan-Baluchistan, can be imported cases from other countries, and often occur  
214 sporadically.

215 Approximately, 3.9 billion people in 129 countries are at risk of contracting DENV worldwide. Almost  
216 70% of this global burden of DENV is related to Asia. According to World Health Organization (WHO),  
217 DENV cases have levitated more than eight times in the last two decades. Several important outbreaks of  
218 DENV have recently happened in the Eastern Mediterranean Regional Organization (EMRO) countries,  
219 including Saudi Arabia, Yemen, Oman, Sudan, and Pakistan. Alarmingly, asymptomatic humans despite  
220 low-medium level of viremia transmit DENV to vector mosquitoes<sup>64</sup>. The inter-epidemic period for  
221 DENV is 3-5 years.

222 The main anthropophilic vector, *Aedes aegypti*, of DENV is a diurnally-active endophilic species. After  
223 seven decades, this mosquito species has re-emerged, particularly in the coastal SE region of Iran. There  
224 are also unconfirmed reports of *Aedes albopictus* presence in the same Oriental provinces of this country.  
225 Pregnant females and immunocompromised individuals, like those with diabetes, allergies, and many  
226 chronic diseases, are specially at risk of being afflicted with DENV.

## 227 **Conclusions**

228 Based on the present systematic review and meta-analysis findings, WNV, CHIKV, and DENV have been  
229 detected in Iran using ELISA test. Considering the prevalence of WNV and CHIKV, and also the  
230 identification of these viruses in several provinces, it could be postulated that these two viruses are  
231 endemic in Iran, while DENV occurs sporadically in Iran. Based on this, to monitor and surveil the spread  
232 and outbreak of these viruses, it is recommended to screen suspected travelers and high-risk cohorts from  
233 highly-endemic neighborhood regions using the ELISA test combined with the more sophisticated  
234 molecular tools such as polymerase chain reactions (PCR).

235 (*N.B.* While this MS was under the submission process, three new fatal cases of DENV were reported  
236 from the SE counties of Fars and Hormozgan provinces, Iran).

237

## 238 **DECLARATIONS**

239 **Funding**

240 No funding was received for this manuscript.

241 **Ethical Approval**

242 Not applicable. No ethical approval is applicable since it is a review article.

243 **Conflict of Interests**

244 The authors declare no conflict of interests.

245 **Data Availability and Materials**

246 The data that support the findings of this study are available from the corresponding author upon  
247 reasonable request

248 **Acknowledgments**

249 The authors wish to convey their appreciation to the Vice-Chancellor for Research and Technology at  
250 Shiraz University of Medical Sciences (SUMS) for provision of software support and other logistics. This  
251 meta-analysis report was part of a self-initiative attempt to screen and elucidate the current status of three  
252 highly-important clinical arboviruses in Iran, forming a basis to the part fulfilment of a PhD thesis by  
253 E.A. under the supervisorship of M.D.M-F. in the Dept. of Biology and Control of Disease Vectors,  
254 School of Health, Shiraz, Iran.

255

## 256 **References**

- 257 1. García-Carrasco J-M, Muñoz A-R, Olivero J, et al. Predicting the spatio-temporal spread of West Nile  
258 virus in Europe. *PLoS neglected tropical diseases* 2021;15(1):e0009022.
- 259 2. Riccò M, Peruzzi S, Balzarini F. Epidemiology of West Nile virus infections in humans, Italy, 2012–  
260 2020: a summary of available evidences. *Tropical Medicine and Infectious Disease* 2021;6(2):61.
- 261 3. Stonedahl S, Clarke P, Tyler KL. The role of microglia during West Nile virus infection of the central  
262 nervous system. *Vaccines* 2020;8(3):485.
- 263 4. Habarugira G, Suen WW, Hobson-Peters J, et al. West Nile virus: an update on pathobiology,  
264 epidemiology, diagnostics, control and “one health” implications. *Pathogens* 2020;9(7):589.
- 265 5. Yu A, Ferenczi E, Moussa K, et al. Clinical spectrum of west nile virus neuroinvasive disease. *The*  
266 *Neurohospitalist* 2020;10(1):43-47.
- 267 6. Sejvar J. Clinical Manifestations and Outcomes of West Nile Virus Infection. *Viruses* 2014;6:606-23.  
268 doi: 10.3390/v6020606
- 269 7. Kaiser J, Barrett A. Twenty Years of Progress Toward West Nile Virus Vaccine Development. 2019  
270 5(9):823. doi: doi: 10.3390/v11090823. PMID: 31491885; PMCID: PMC6784102
- 271 8. Tamba M, Bonilauri P, Galletti G, et al. West Nile virus surveillance using sentinel birds: results of  
272 eleven years of testing in corvids in a region of northern Italy. *Frontiers in Veterinary Science*  
273 2024;11:1407271.
- 274 9. Moirano G, Richiardi L, Calzolari M, et al. Recent rapid changes in the spatio-temporal distribution of  
275 West Nile Neuro-invasive Disease in Italy. *Zoonoses and public health* 2020;67(1):54-61.
- 276 10. Moirano G, Gasparini A, Acquotta F, et al. West Nile Virus infection in Northern Italy: Case-  
277 crossover study on the short-term effect of climatic parameters. *Environmental Research*  
278 2018;167 doi: 10.1016/j.envres.2018.08.016
- 279 11. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*  
280 2013;496(7446):504-07.
- 281 12. Carrington LB, Simmons CP. Human to mosquito transmission of dengue viruses. *Frontiers in*  
282 *immunology* 2014;5:86757.
- 283 13. Chen R, Vasilakis N. Dengue—quo tu et quo vadis? *Viruses* 2011;3(9):1562-608.
- 284 14. Shepard DS, Undurraga EA, Halasa YA, et al. The global economic burden of dengue: a systematic  
285 analysis. *The Lancet infectious diseases* 2016;16(8):935-41.
- 286 15. Wu W, Bai Z, Zhou H, et al. Molecular epidemiology of dengue viruses in southern China from 1978  
287 to 2006. *Virology journal* 2011;8:1-9.
- 288 16. Wahala WM, De Silva AM. The human antibody response to dengue virus infection. *Viruses*  
289 2011;3(12):2374-95.
- 290 17. Ferreira JM, Dutra JCV, dos Santos BRC, et al. Arboviruses (Alphavirus) related to autoimmune  
291 rheumatic diseases: Triggers and possible therapeutic interventions. *Translational Autoimmunity:*  
292 Elsevier 2023:543-64.
- 293 18. de Lima Cavalcanti TYV, Pereira MR, de Paula SO, et al. A review on chikungunya virus  
294 epidemiology, pathogenesis and current vaccine development. *Viruses* 2022;14(5):969.
- 295 19. Wahid B, Ali A, Rafique S, et al. Global expansion of chikungunya virus: mapping the 64-year  
296 history. *International journal of infectious diseases : IJID : official publication of the*  
297 *International Society for Infectious Diseases* 2017;58:69-76. doi: 10.1016/j.ijid.2017.03.006  
298 [published Online First: 2017/03/16]
- 299 20. Ferreira FCPdADM, da Silva ASV, Recht J, et al. Vertical transmission of chikungunya virus: A  
300 systematic review. *PLoS One* 2021;16(4):e0249166.
- 301 21. Agarwal A, Dash PK, Singh AK, et al. Evidence of experimental vertical transmission of emerging  
302 novel ECSA genotype of Chikungunya Virus in *Aedes aegypti*. *PLoS Negl Trop Dis*  
303 2014;8(7):e2990. doi: 10.1371/journal.pntd.0002990 [published Online First: 2014/08/01]
- 304 22. Diallo D, Sall AA, Buenemann M, et al. Landscape ecology of sylvatic chikungunya virus and  
305 mosquito vectors in southeastern Senegal. *PLoS Negl Trop Dis* 2012;6(6):e1649. doi:  
306 10.1371/journal.pntd.0001649 [published Online First: 2012/06/22]



- 307 23. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and  
308 prospective intervention strategies. *The Journal of clinical investigation* 2017;127(3):737-49. doi:  
309 10.1172/jci84417 [published Online First: 2017/03/02]
- 310 24. Appassakij H, Khuntikij P, Kemapunmanus M, et al. Viremic profiles in asymptomatic and  
311 symptomatic chikungunya fever: a blood transfusion threat? *Transfusion* 2013;53(10 Pt 2):2567-  
312 74. doi: 10.1111/j.1537-2995.2012.03960.x [published Online First: 2012/11/28]
- 313 25. Cunha RVD, Trinta KS. Chikungunya virus: clinical aspects and treatment - A Review. *Memorias do*  
314 *Instituto Oswaldo Cruz* 2017;112(8):523-31. doi: 10.1590/0074-02760170044 [published Online  
315 First: 2017/08/03]
- 316 26. Tritsch SR, Encinales L, Pacheco N, et al. Chronic Joint Pain 3 Years after Chikungunya Virus  
317 Infection Largely Characterized by Relapsing-remitting Symptoms. *The Journal of rheumatology*  
318 2020;47(8):1267-74. doi: 10.3899/jrheum.190162 [published Online First: 2019/07/03]
- 319 27. Chang AY, Encinales L, Porras A, et al. Frequency of Chronic Joint Pain Following Chikungunya  
320 Virus Infection: A Colombian Cohort Study. *Arthritis & rheumatology (Hoboken, NJ)*  
321 2018;70(4):578-84. doi: 10.1002/art.40384 [published Online First: 2017/12/22]
- 322 28. Murillo-Zamora E, Mendoza-Cano O, Trujillo-Hernández B, et al. Persistent arthralgia and related  
323 risks factors in laboratory-confirmed cases of Chikungunya virus infection in Mexico. *Revista*  
324 *Panamericana de Salud Pública* 2017;41:e72.
- 325 29. Aghaie A, Aaskov J, Chinikar S, et al. Frequency of West Nile virus infection in Iranian blood  
326 donors. *Indian Journal of Hematology and Blood Transfusion* 2016;32:343-46.
- 327 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-  
328 analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1.
- 329 31. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in  
330 Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International*  
331 *journal of surgery* 2014;12(12):1495-99.
- 332 32. Amin M, Zaim M, Edalat H, et al. Seroprevalence study on West Nile virus (WNV) infection, a  
333 hidden viral disease in fars province, southern Iran. *Journal of Arthropod-Borne Diseases*  
334 2020;14(2):173.
- 335 33. Babahajian A, Sharifi P, Babahajiani W, et al. Seroprevalence of West Nile Virus in Regular Blood  
336 Donors Referred to the Blood Bank of Kurdistan Province, Iran. *Sudan Journal of Medical*  
337 *Sciences* 2022;17(2):192-203.
- 338 34. Chinikar S, Shah-Hosseini N, Mostafavi E, et al. Seroprevalence of west nile virus in iran. *Vector-*  
339 *Borne and Zoonotic Diseases* 2013;13(8):586-89.
- 340 35. Kalantari M, Salehi-Vaziri M, Pouriayevali MH, et al. Seroprevalence of West Nile virus in  
341 Khuzestan province, southwestern Iran, 2016–2017. *Journal of Vector Borne Diseases*  
342 2019;56(3):263-67.
- 343 36. Meshkat Z, Chinikar S, Shakeri M, et al. Prevalence of West Nile virus in Mashhad, Iran: A  
344 population–based study. *Asian Pacific journal of tropical medicine* 2015;8(3):203-05.
- 345 37. Sharifi Z, MAHMOUDIAN SM, Talebian A. A study of West Nile virus infection in Iranian blood  
346 donors. 2010
- 347 38. Solgi A, Karimi A, Armin S. Seropositivity of chikungunya and West Nile viruses in Iranian children  
348 in 2018. *Archives of Pediatric Infectious Diseases* 2020;8(2)
- 349 39. Ziyaeyan M, Behzadi MA, Leyva-Grado VH, et al. Widespread circulation of West Nile virus, but not  
350 Zika virus in southern Iran. *PLoS Neglected Tropical Diseases* 2018;12(12):e0007022.
- 351 40. Pouriayevali MH, Rezaei F, Jalali T, et al. Imported cases of Chikungunya virus in Iran. *BMC*  
352 *Infectious Diseases* 2019;19:1-8.
- 353 41. Poudine M, Parsi-Moud A, Mohagheghi-Fard AH, et al. Seroprevalence of Chikungunya Virus  
354 Infection in Sistan and Baluchestan Province, Iran: A Pilot Study. *Archives of Clinical Infectious*  
355 *Diseases* 2023;18(6)
- 356 42. Khalili M, Aflatoonian MR, Hemati M, et al. Dengue fever serology in febrile patients in Southeast  
357 Iran. *Journal of Kerman University of Medical Sciences* 2019;26(1):90-94.

- 358 43. Aghaie A, Aaskov J, Chinikar S, et al. Frequency of dengue virus infection in blood donors in Sistan  
359 and Baluchestan province in Iran. *Transfus Apher Sci* 2014;50(1):59-62. doi:  
360 10.1016/j.transci.2013.07.034 [published Online First: 2013/12/18]
- 361 44. Sotelo E, Gutierrez-Guzmán AV, del Amo J, et al. Pathogenicity of two recent Western  
362 Mediterranean West Nile virus isolates in a wild bird species indigenous to Southern Europe: the  
363 red-legged partridge. *Veterinary Research* 2011;42:1-8.
- 364 45. Wallace MR, Hale BR, Utz GC, et al. Endemic infectious diseases of Afghanistan. *Clinical Infectious  
365 Diseases* 2002;34(Supplement\_5):S171-S207.
- 366 46. Kalaycioglu H, Korukluoglu G, Ozkul A, et al. Emergence of West Nile virus infections in humans in  
367 Turkey, 2010 to 2011. *Eurosurveillance* 2012;17(21):20182.
- 368 47. Humphrey JM, Al-Absi ES, Hamdan MM, et al. Dengue and chikungunya seroprevalence among  
369 Qatari nationals and immigrants residing in Qatar. *PloS one* 2019;14(1):e0211574.
- 370 48. Khan E, Barr KL, Farooqi JQ, et al. Human West Nile virus disease outbreak in Pakistan, 2015–2016.  
371 *Frontiers in public health* 2018;6:20.
- 372 49. Elyan DS, Moustafa L, Noormal B, et al. Serological evidence of Flaviviruses infection among acute  
373 febrile illness patients in Afghanistan. *The Journal of Infection in Developing Countries*  
374 2014;8(09):1176-80.
- 375 50. Eybpoosh S, Fazlalipour M, Baniasadi V, et al. Epidemiology of West Nile Virus in the Eastern  
376 Mediterranean region: A systematic review. *PLoS neglected tropical diseases*  
377 2019;13(1):e0007081.
- 378 51. Platonov AE, Fedorova MV, Karan LS, et al. Epidemiology of West Nile infection in Volgograd,  
379 Russia, in relation to climate change and mosquito (Diptera: Culicidae) bionomics. *Parasitology  
380 research* 2008;103:45-53.
- 381 52. Moro ML, Gagliotti C, Silvi G, et al. Chikungunya virus in North-Eastern Italy: a seroprevalence  
382 survey. *The American journal of tropical medicine and hygiene* 2010;82(3):508.
- 383 53. Balasubramaniam SM, Krishnakumar J, Stephen T, et al. Prevalence of chikungunya in urban field  
384 practice area of a private medical college, Chennai. *Indian Journal of Community Medicine*  
385 2011;36(2):124-27.
- 386 54. Kajeguka DC, Kaaya RD, Mwakalinga S, et al. Prevalence of dengue and chikungunya virus  
387 infections in north-eastern Tanzania: a cross sectional study among participants presenting with  
388 malaria-like symptoms. *BMC infectious diseases* 2016;16:1-9.
- 389 55. Atalay T, Kaygusuz S, Azkur AK. A study of the chikungunya virus in humans in Turkey. *Turkish  
390 Journal of Medical Sciences* 2017;47(4):1161-64.
- 391 56. Humphrey JM, Cleton NB, Reusken CB, et al. Urban chikungunya in the Middle East and North  
392 Africa: a systematic review. *PLoS neglected tropical diseases* 2017;11(6):e0005707.
- 393 57. Chinikar S, Ghiasi S, Moradi M, et al. Laboratory detection facility of dengue fever (DF) in Iran: the  
394 first imported case. *Int J Infect Dis* 2010;8(1):1-2.
- 395 58. Mardani M, Abbasi F, Aghahasani M, et al. First Iranian imported case of dengue. *International  
396 journal of preventive medicine* 2013;4(9):1075.
- 397 59. Wilder-Smith A, Chen LH, Massad E, et al. Threat of dengue to blood safety in dengue-endemic  
398 countries. *Emerging infectious diseases* 2009;15(1):8.
- 399 60. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. *Nature reviews  
400 microbiology* 2010;8(Suppl 12):S7-S16.
- 401 61. Eldigail MH, Adam GK, Babiker RA, et al. Prevalence of dengue fever virus antibodies and  
402 associated risk factors among residents of El-Gadarif state, Sudan. *BMC public health* 2018;18:1-  
403 8.
- 404 62. Kumar M, Verma RK, Mishra B. Prevalence of dengue fever in Western Uttar Pradesh, India: a  
405 gender-based study. *International Journal of Applied and Basic Medical Research* 2020;10(1):8-  
406 11.
- 407 63. Wiwanitkit V. Non vector-borne transmission modes of dengue. *Journal of Infection in Developing  
408 Countries* 2010;4(1)

409 64. Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes.  
410 *Proc Natl Acad Sci U S A* 2015;112(47):14688-93. doi: 10.1073/pnas.1508114112 [published  
411 Online First: 2015/11/11]

412

413

414

415

416

## 417 **List of Legends**

418 **Fig 1.** The review process based on PRISMA flow chart.

419 **Fig 2.** Pooled prevalence of positive ELISA test for West Nile virus in Iran based on the random effects  
420 model. The midpoint of each line segment shows the prevalence estimate, the length of the line segment  
421 indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled  
422 prevalence.

423 **Fig 3.** Pooled prevalence of positive ELISA test for Chikungunya virus in Iran based on random effects  
424 model. The midpoint of each line segment shows the prevalence estimate, the length of the line segment  
425 indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled  
426 prevalence.

427 **Fig 4.** Funnel plot of the prevalence positive ELISA test in the selected studies.

428 **Fig 5.** Meta-regression plot of prevalence of West Nile virus and sample size of study.

429

430

431

432

433


434

435

436

437  
438


439 **Figure legend**



464 **Figure 1.** The review process based on PRISMA flow chart

465

466




468 **Figure 2.** Pooled prevalence of positive ELISA test for West Nile virus in Iran based on the random  
 469 effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line  
 470 segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled  
 471 prevalence.

472

473

474




475

476 **Figure 3.** Pooled prevalence of positive ELISA test for Chikungunya virus in Iran based on random  
477 effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line  
478 segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled  
479 prevalence.

480


481



482

483

**Figure 4.** Funnel plot of the prevalence positive ELISA test in the selected studies.



484

485

**Figure 5.** Meta-regression plot of prevalence of West Nile virus and sample size of study.

486

487

488

489

490

491

492

493

494

495



496 **Table legends**

497 **Table 1.** Characteristics of the articles included in the meta-analysis

Author (ref.)	Place of study	Year of publication	Sample Size	Type of virus	Type of serological test
Sharifi Z <sup>37</sup>	Tehran	2010	500	WNV	ELISA
Meshkat Z <sup>36</sup>	Mashhad	2015	182	WNV	ELISA
Aghaie A <sup>29</sup>	Chabahar	2016	540	WNV and DENV	ELISA
Solgi A <sup>38</sup>	Tehran	2020	180	WNV and CHIKV	ELISA
Chinikar S <sup>34</sup>	Golestan, Qom and Gilan	2013	300	WNV	ELISA
Babahajian A <sup>33</sup>	Kurdistan	2022	259	WNV	ELISA
Amin M <sup>32</sup>	Fars	2020	150	WNV	ELISA
Kalantari M <sup>35</sup>	Khuzestan	2019	408	WNV	ELISA
Ziyaeyan M <sup>39</sup>	Hormozgan	2018	494	WNV	ELISA
Khalili M <sup>42</sup>	Sistan-Baluchistan, Kerman and South Khorasan	2019	184	DENV	ELISA
Pouriayevali MH <sup>40</sup>	Sistan-Baluchistan	2019	151	CHIKV	ELISA
Poudine M <sup>41</sup>	Sistan-Baluchistan	2023	203	CHIKV	ELISA

498

499

500

501

502

503